Ignite Creation Date:
2025-12-24 @ 4:02 PM
Ignite Modification Date:
2025-12-31 @ 2:16 PM
Study NCT ID:
NCT04909866
Status:
UNKNOWN
Last Update Posted:
2021-06-02
First Post:
2021-02-09
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
The Efficacy and Safety of TACE, Lenvatinib and Camrelizumab in the Treatment of BCLC Stage B/C Hepatocellular Carcinoma: a Single-arm, Single-center, Open-label Study
Sponsor:
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2021-01-01
Start Date Type:
ACTUAL
Primary Completion Date:
2022-09-01
Primary Completion Date Type:
ESTIMATED
Completion Date:
2022-12-01
Completion Date Type:
ESTIMATED
First Submit Date:
2021-02-09
First Submit QC Date:
None
Study First Post Date:
2021-06-02
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2021-05-27
Last Update Post Date:
2021-06-02
Last Update Post Date Type:
ACTUAL